NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.

Sponsor:

Lene Meldgaard Knudsen

Collaborator:

IO Biotech

Locations

Denmark

---

ClinicalTrials.gov Identifier: NCT03850522

Official Title: Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma

First Posted : February 21, 2019

https://clinicaltrials.gov/ct2/show/NCT03850522

---

Biological: PD-L1 peptide

---

PD-L1 Peptide Vaccine

PD-L1 Peptide Vaccine (Code C148146)

PD-L1 Peptide

PD-L1 Peptide Vaccine